|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2018. CA Cancer J Clin. 68:7–30. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Lawrence MS, Stojanov P, Polak P, Kryukov
GV, Cibulskis K, Sivachenko A, Carter SL, Stewart C, Mermel CH,
Roberts SA, et al: Mutational heterogeneity in cancer and the
search for new cancer-associated genes. Nature. 499:214–218. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Ferrara R, Mezquita L, Texier M, Lahmar J,
Audigier-Valette C, Tessonnier L, Mazieres J, Zalcman G, Brosseau
S, Le Moulec S, et al: Hyperprogressive disease in patients with
advanced non-small cell lung cancer treated With PD-1/PD-L1
inhibitors or with single-agent chemotherapy. JAMA Oncol.
4:1543–1552. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Park CK, Cho HJ, Choi YD, Oh IJ and Kim
YC: A phase II trial of osimertinib in the second-line treatment of
non-small cell lung cancer with the EGFR T790M mutation, detected
from circulating tumor DNA: LiquidLung-O-Cohort 2. Cancer Res
Treat. 51:777–787. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Barrett T, Wilhite SE, Ledoux P,
Evangelista C, Kim IF, Tomashevsky M, Marshall KA, Phillippy KH,
Sherman PM, Holko M, et al: NCBI GEO: Archive for functional
genomics data sets-update. Nucleic Acids Res. 41((Database Issue)):
D991–D995. 2013.PubMed/NCBI
|
|
6
|
Robles AI, Arai E, Mathé EA, Okayama H,
Schetter AJ, Brown D, Petersen D, Bowman ED, Noro R, Welsh JA, et
al: An Integrated prognostic classifier for stage I lung
adenocarcinoma based on mRNA, microRNA, and DNA methylation
biomarkers. J Thorac Oncol. 10:1037–1048. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Selamat SA, Chung BS, Girard L, Zhang W,
Zhang Y, Campan M, Siegmund KD, Koss MN, Hagen JA, Lam WL, et al:
Genome-scale analysis of DNA methylation in lung adenocarcinoma and
integration with mRNA expression. Genome Res. 22:1197–1211. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Girard L, Rodriguez-Canales J, Behrens C,
Thompson DM, Botros IW, Tang H, Xie Y, Rekhtman N, Travis WD,
Wistuba II, et al: An expression signature as an aid to the
histologic classification of non-small cell lung cancer. Clin
Cancer Res. 22:4880–4889. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Huang DW, Sherman BT, Tan Q, Collins JR,
Alvord WG, Roayaei J, Stephens R, Baseler MW, Lane HC and Lempicki
RA: The DAVID Gene Functional Classification Tool: A novel
biological module-centric algorithm to functionally analyze large
gene lists. Genome Biol. 8:R1832007. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Tanabe M and Kanehisa M: Using the KEGG
database resource. Curr Protoc Bioinformatics Chapter 1. Unit 1.12.
2012. View Article : Google Scholar
|
|
11
|
Szklarczyk D, Morris JH, Cook H, Kuhn M,
Wyder S, Simonovic M, Santos A, Doncheva NT, Roth A, Bork P, et al:
The STRING database in 2017: Quality-controlled protein-protein
association networks, made broadly accessible. Nucleic Acids Res.
45:D362–D368. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Shannon P, Markiel A, Ozier O, Baliga NS,
Wang JT, Ramage D, Amin N, Schwikowski B and Ideker T: Cytoscape: A
software environment for integrated models of biomolecular
interaction networks. Genome Res. 13:2498–2504. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Kwon S, Kim H and Kim HS: Identification
of pharmacologically tractable protein complexes in cancer using
the R-based network clustering and visualization program MCODER.
BioMed Res Int. 2017:10163052017. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Demchak B, Hull T, Reich M, Liefeld T,
Smoot M, Ideker T and Mesirov JP: Cytoscape: The network
visualization tool for GenomeSpace workflows. Version 2. F1000Res.
3:1512014. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Cerami E, Gao J, Dogrusoz U, Gross BE,
Sumer SO, Aksoy BA, Jacobsen A, Byrne CJ, Heuer ML, Larsson E, et
al: The cBio cancer genomics portal: An open platform for exploring
multidimensional cancer genomics data. Cancer Discov. 2:401–404.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Maere S, Heymans K and Kuiper M: BiNGO: A
Cytoscape plugin to assess overrepresentation of gene ontology
categories in biological networks. Bioinformatics. 21:3448–3449.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Casper J, Zweig AS, Villarreal C, Tyner C,
Speir ML, Rosenbloom KR, Raney BJ, Lee CM, Lee BT, Karolchik D, et
al: The UCSC Genome Browser database: 2018 update. Nucleic Acids
Res. 46:D762–D769. 2018.PubMed/NCBI
|
|
18
|
Rhodes DR, Kalyana-Sundaram S, Mahavisno
V, Varambally R, Yu J, Briggs BB, Barrette TR, Anstet MJ,
Kincead-Beal C, Kulkarni P, et al: Oncomine 3.0: Genes, pathways,
and networks in a collection of 18,000 cancer gene expression
profiles. Neoplasia. 9:166–180. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Dong S, Qu X, Li W, Zhong X, Li P, Yang S,
Chen X, Shao M and Zhang L: The long non-coding RNA, GAS5, enhances
gefitinib-induced cell death in innate EGFR tyrosine kinase
inhibitor-resistant lung adenocarcinoma cells with wide-type EGFR
via downregulation of the IGF-1R expression. J Hematol Oncol.
8:432015. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Labbé DP, Sweeney CJ, Brown M, Galbo P,
Rosario S, Wadosky KM, Ku SY, Sjöström M, Alshalalfa M, Erho N, et
al: TOP2A and EZH2 provide early detection of an aggressive
prostate cancer subgroup. Clin Cancer Res. 23:7072–7083. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Rouquier S, Pillaire MJ, Cazaux C and
Giorgi D: Expression of the microtubule-associated protein
MAP9/ASAP and its partners AURKA and PLK1 in colorectal and breast
cancers. Dis Markers. 2014:7981702014. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Beer DG, Kardia SL, Huang CC, Giordano TJ,
Levin AM, Misek DE, Lin L, Chen G, Gharib TG, Thomas DG, et al:
Gene-expression profiles predict survival of patients with lung
adenocarcinoma. Nat Med. 8:816–824. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Hou J, Aerts J, den Hamer B, van Ijcken W,
den Bakker M, Riegman P, van der Leest C, van der Spek P, Foekens
JA, Hoogsteden HC, et al: Gene expression-based classification of
non-small cell lung carcinomas and survival prediction. PLoS One.
5:e103122010. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Landi MT, Dracheva T, Rotunno M, Figueroa
JD, Liu H, Dasgupta A, Mann FE, Fukuoka J, Hames M, Bergen AW, et
al: Gene expression signature of cigarette smoking and its role in
lung adenocarcinoma development and survival. PLoS One.
3:e16512008. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Su LJ, Chang CW, Wu YC, Chen KC, Lin CJ,
Liang SC, Lin CH, Whang-Peng J, Hsu SL, Chen CH and Huang CY:
Selection of DDX5 as a novel internal control for Q-RT-PCR from
microarray data using a block bootstrap re-sampling scheme. BMC
Genomics. 8:1402007. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Yamagata N, Shyr Y, Yanagisawa K, Edgerton
M, Dang TP, Gonzalez A, Nadaf S, Larsen P, Roberts JR, Nesbitt JC,
et al: A training-testing approach to the molecular classification
of resected non-small cell lung cancer. Clin Cancer Res.
9:4695–4704. 2003.PubMed/NCBI
|
|
27
|
Bhattacharjee A, Richards WG, Staunton J,
Li C, Monti S, Vasa P, Ladd C, Beheshti J, Bueno R, Gillette M, et
al: Classification of human lung carcinomas by mRNA expression
profiling reveals distinct adenocarcinoma subclasses. Proc Natl
Acad Sci USA. 98:13790–13795. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Garber ME, Troyanskaya OG, Schluens K,
Petersen S, Thaesler Z, Pacyna-Gengelbach M, van de Rijn M, Rosen
GD, Perou CM, Whyte RI, et al: Diversity of gene expression in
adenocarcinoma of the lung. Proc Natl Acad Sci USA. 98:13784–13789.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Bray F, Ferlay J, Soerjomataram I, Siegel
RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN
estimates of incidence and mortality worldwide for 36 cancers in
185 countries. CA Cancer J Clin. 68:394–424. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Li Y, Juhasz AL, Ma LQ and Cui X:
Inhalation bioaccessibility of PAHs in PM2.5:
Implications for risk assessment and toxicity prediction. Sci Total
Environ. 650:56–64. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Papadopoulos A, Guida F, Cénée S, Cyr D,
Schmaus A, Radoï L, Paget-Bailly S, Carton M, Tarnaud C, Menvielle
G, et al: Cigarette smoking and lung cancer in women: Results of
the French ICARE case-control study. Lung Cancer. 74:369–377. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Sekine T, Sakaguchi C and Fukano Y:
Investigation by microarray analysis of effects of cigarette design
characteristics on gene expression in human lung mucoepidermoid
cancer cells NCI-H292 exposed to cigarette smoke. Exp Toxicol
Pathol. 67:143–151. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Huang Z, Su R, Qing C, Peng Y, Luo Q and
Li J: Plasma circular RNAs hsa_circ_0001953 and hsa_circ_0009024 as
diagnostic biomarkers for active tuberculosis. Front Microbiol.
9:20102018. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Tan TZ, Rouanne M, Tan KT, Huang RY and
Thiery JP: Molecular subtypes of urothelial bladder cancer: Results
from a meta-cohort analysis of 2411 tumors. Eur Urol. 75:423–432.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Li SY, Wu HC, Mai HF, Zhen JX, Li GS and
Chen SJ: Microarray-based analysis of whole-genome DNA methylation
profiling in early detection of breast cancer. J Cell Biochem.
120:658–670. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Miao S, Qiu T, Zhao Y, Wang H, Sun X, Wang
Y, Xuan Y, Qin Y and Jiao W: Overexpression of S100A13 protein is
associated with tumor angiogenesis and poor survival in patients
with early-stage non-small cell lung cancer. Thorac Cancer.
9:1136–1144. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Eser PO and Jänne PA: TGFβ pathway
inhibition in the treatment of non-small cell lung cancer.
Pharmacol Ther. 184:112–130. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Basu AK: DNA damage, mutagenesis and
cancer. Int J Mol Sci. 19:E9702018. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Park CW, Bak Y, Kim MJ, Srinivasrao G,
Hwang J, Sung NK, Kim BY, Yu JH, Hong JT and Yoon DY: The novel
small molecule STK899704 promotes senescence of the human A549
NSCLC cells by inducing DNA damage responses and cell cycle arrest.
Front Pharmacol. 9:1632018. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Li L, Lei Q, Zhang S, Kong L and Qin B:
Screening and identification of key biomarkers in hepatocellular
carcinoma: Evidence from bioinformatic analysis. Oncol Rep.
38:2607–2618. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Knez L, Sodja E, Kern I, Košnik M and
Cufer T: Predictive value of multidrug resistance proteins,
topoisomerases II and ERCC1 in small cell lung cancer: A systematic
review. Lung Cancer. 72:271–279. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Huang H, Liu J, Meng Q and Niu G:
Multidrug resistance protein and topoisomerase 2 alpha expression
in non-small cell lung cancer are related with brain metastasis
postoperatively. Int J Clin Exp Pathol. 8:11537–11542.
2015.PubMed/NCBI
|
|
43
|
Sudan S and Rupasinghe HP:
Quercetin-3-O-glucoside induces human DNA topoisomerase II
inhibition, cell cycle arrest and apoptosis in hepatocellular
carcinoma cells. Anticancer Res. 34:1691–1699. 2014.PubMed/NCBI
|
|
44
|
Kaur G, Reinhart RA, Monks A, Evans D,
Morris J, Polley E and Teicher BA: Bromodomain and hedgehog pathway
targets in small cell lung cancer. Cancer Lett. 371:225–239. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Shi R, Sun Q, Sun J, Wang X, Xia W, Dong
G, Wang A, Jiang F and Xu L: Cell division cycle 20 overexpression
predicts poor prognosis for patients with lung adenocarcinoma.
Tumour Biol. 39:10104283176922332017. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Klaeger S, Heinzlmeir S, Wilhelm M, Polzer
H, Vick B, Koenig PA, Reinecke M, Ruprecht B, Petzoldt S, Meng C,
et al: The target landscape of clinical kinase drugs. Science.
358:eaan43682017. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Lazaris AC, Kavantzas NG, Zorzos HS,
Tsavaris NV and Davaris PS: Markers of drug resistance in relapsing
colon cancer. J Cancer Res Clin Oncol. 128:114–118. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Costa MJ, Hansen CL, Holden JA and Guinee
D Jr: Topoisomerase II alpha: Prognostic predictor and cell cycle
marker in surface epithelial neoplasms of the ovary and peritoneum.
Int J Gynecol Pathol. 19:248–257. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Taylor NJ, Bensen JT, Poole C, Troester
MA, Gammon MD, Luo J, Millikan RC and Olshan AF: Genetic variation
in cell cycle regulatory gene AURKA and association with intrinsic
breast cancer subtype. Mol Carcinog. 54:1668–1677. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Hoque A, Carter J, Xia W, Hung MC, Sahin
AA, Sen S and Lippman SM: Loss of aurora A/STK15/BTAK
overexpression correlates with transition of in situ to invasive
ductal carcinoma of the breast. Cancer Epidemiol Biomarkers Prev.
12:1518–1522. 2003.PubMed/NCBI
|
|
51
|
Zhou H, Kuang J, Zhong L, Kuo WL, Gray JW,
Sahin A, Brinkley BR and Sen S: Tumour amplified kinase STK15/BTAK
induces centrosome amplification, aneuploidy and transformation.
Nat Genet. 20:189–193. 1998. View
Article : Google Scholar : PubMed/NCBI
|
|
52
|
Staff S, Isola J, Jumppanen M and Tanner
M: Aurora-A gene is frequently amplified in basal-like breast
cancer. Oncol Rep. 23:307–312. 2010.PubMed/NCBI
|
|
53
|
Lukasiewicz KB and Lingle WL: Aurora A,
centrosome structure, and the centrosome cycle. Environ Mol
Mutagen. 50:602–619. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Melichar B, Adenis A, Lockhart AC,
Bennouna J, Dees EC, Kayaleh O, Obermannova R, DeMichele A,
Zatloukal P, Zhang B, et al: Safety and activity of alisertib, an
investigational aurora kinase A inhibitor, in patients with breast
cancer, small-cell lung cancer, non-small-cell lung cancer, head
and neck squamous-cell carcinoma, and gastro-oesophageal
adenocarcinoma: A five-arm phase 2 study. Lancet Oncol. 16:395–405.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Chen J, Lu H, Zhou W, Yin H, Zhu L, Liu C,
Zhang P, Hu H, Yang Y and Han H: AURKA upregulation plays a role in
fibroblast-reduced gefitinib sensitivity in the NSCLC cell line
HCC827. Oncol Rep. 33:1860–1866. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Duan L, Ye L, Zhuang L, Zou X, Liu S,
Zhang Y, Zhang L, Jin C and Huang Y: VEGFC/VEGFR3 axis mediates
TGFβ1-induced epithelial-to-mesenchymal transition in non-small
cell lung cancer cells. PLoS One. 13:e02004522018. View Article : Google Scholar : PubMed/NCBI
|
